Año: 2024

Adani Group is under fire again, with its shares seeing significant volatility following fresh accusations from short-selling firm Hindenburg Research. Hindenburg’s latest report accuses the chairman of India’s Securities and Exchange Board of India (SEBI) of potential conflicts of interest, casting doubt on the regulator’s impartiality in its investigation into the conglomerate. The allegations have reignited concerns about corporate governance and financial transparency at Adani Group. Although the group's share prices initially fell, they managed to recover some of their losses by the end of the trading day. However, the ongoing saga highlights the fragile investor sentiment surrounding the Adani…

The 2024 Paris Olympics saw the United States reclaim the gold medal in men's basketball, but the victory was not without controversy. The decision to limit Jayson Tatum's playing time sparked debate and raised questions about the team's strategy. As the United States looks ahead to the 2028 Los Angeles Games, the challenge of balancing established superstars with emerging talent will be paramount. While legends like LeBron James and Stephen Curry have dominated the international scene, the next generation of players, including Tatum, Anthony Edwards and Jalen Green, are eager to make their mark. The delicate balance between experience and…

Pharmaceutical giant Eli Lilly delivered a stellar second-quarter performance, beating analysts’ expectations and raising its full-year outlook by a whopping $3 billion. The company’s flagship diabetes drug, Mounjaro, and its weight-loss counterpart, Zepbound, were the main drivers of the stellar growth. Mounjaro and Zepbound, both incretin drugs, have seen unprecedented demand, leading to supply constraints that Eli Lilly is aggressively addressing. The company has invested heavily in expanding manufacturing capacity, resulting in a 50% increase in production of these drugs in the second half of 2024 versus the prior year. Despite supply challenges, Eli Lilly’s revenues increased 36% year-over-year to…

In a significant move in the financial sector, UK-based investment firm Hargreaves Lansdown has confirmed it has accepted a £5.4 billion ($6.9 billion) buyout offer from a consortium led by CVC Group. The deal, announced Friday by its Bristol headquarters, also involves stakes in Abu Dhabi’s sovereign wealth fund and Nordic Capital, marking the proposal as final. Under the terms of the deal, Hargreaves Lansdown shareholders will receive 1,110p per share plus a further 30p per share as a dividend. Following the announcement, the company's shares rose 2.2% in morning trading. The development comes after an earlier £4.7bn offer from…